Ticker: SRPT

Sarepta Therapeutics (SRPT) faces turmoil after a second death linked to its gene therapy Elevidys, causing shares to drop nearly 35%. Analysts BMO and Piper Sandler have downgraded the stock and reduced revenue estimates, raising concerns over safety and regulatory scrutiny.

Biotech stocks plummet up to 10% after FDA official Dr. Peter Marks announces his resignation. Concerns over delayed reviews for innovative therapies loom large, prompting market uncertainty. Traders should monitor FDA developments closely.